| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.3.CO;2-2 |
| P698 | PubMed publication ID | 9708948 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | White DE | |
| Kammula US | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 797-805 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer | |
| P478 | volume | 83 |
| Q33909568 | A new in-silico method for determination of helical transmembrane domains based on the PepLook scan: application to IL-2Rβ and IL-2Rγc receptor chains. |
| Q37267697 | A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma |
| Q36466018 | Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo |
| Q33736534 | Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool |
| Q24644774 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy |
| Q36760292 | Advances in prostate cancer immunotherapies |
| Q37702515 | BRAF and beyond: Tailoring strategies for the individual melanoma patient |
| Q24685049 | Biological response modifiers in cancer |
| Q36612144 | CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. |
| Q37570109 | Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes |
| Q30500830 | Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. |
| Q83155753 | Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma |
| Q36710382 | Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma |
| Q56895279 | Emerging immune therapy of metastatic melanoma in the older patient: does age really matter? |
| Q37021699 | Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance |
| Q24802736 | Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration |
| Q36064163 | Genetic biomarkers of depression |
| Q59400683 | High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 |
| Q59335763 | Hypothalamus-Pituitary-Adrenal Dysfunction in Cholestatic Liver Disease |
| Q50004232 | IL-2 and Beyond in Cancer Immunotherapy |
| Q34423519 | IL-2: the first effective immunotherapy for human cancer. |
| Q50644902 | IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid. |
| Q36713763 | Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction |
| Q34219970 | Immunotherapy for metastatic solid cancers |
| Q56897379 | Immunotherapy of melanoma |
| Q29617326 | Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression |
| Q27011232 | Novel immunotherapeutic strategies of gastric cancer treatment |
| Q37596748 | PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases |
| Q24798836 | Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling |
| Q45148594 | Production of functional native human interleukin-2 in tobacco chloroplasts |
| Q34278609 | Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. |
| Q34536176 | Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer |
| Q45163749 | Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes |
| Q57807469 | Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2 |
| Q34577575 | Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward |
| Q34582536 | Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases |
| Q51211840 | The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. |
| Q37369953 | The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma |
| Q37258968 | The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics |
| Q42868337 | The emergence of modern cancer immunotherapy |
| Q64255024 | Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition |
| Q33631960 | Tumor Therapy Applying Membrane-bound Form of Cytokines |
Search more.